AstraZeneca said today that preliminary data from a trial it conducted on its Covid-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha, and Gamma, when given as a third booster dose.

The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.

AstraZeneca has developed the...